Molecular structure of Nadifloxacin, CAS Number: 124858-35-1
Nadifloxacin (CAS 124858-35-1)
See product citations (2)
Alternate Names:
9-Fluoro-6,7-dihydro-8-(4-hydroxypiperidino)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid; Jinofloxacin
Application:
Nadifloxacin is a fluoroquinolone broad spectrum antibiotic
CAS Number:
124858-35-1
Purity:
>98%
Molecular Weight:
360.38
Molecular Formula:
C19H21FN2O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Nadifloxacin is a cell-permeable, synthetic, broad-spectrum fluoroquinolone antibiotic that inhibits the growth of both gram-positive and gram-negative microbes. Studies suggest that the mechanism of inhibition occurs by interfering with DNA replication. Specifically Nadifloxacin suppresses gram-positive bacterial growth by targeting topoisomerase IV and suppresses gram-negative bacteria by inhibiting Topo II (DNA gyrase), which both function to relax postive supercoils before DNA replication. Furthermore, Nadifloxacin can decrease superoxide radical anions such as O2- and OH-, produced by neutrophils.
Nadifloxacin (CAS 124858-35-1) References
- Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. | Kuwahara, K., et al. 2005. J Dermatol Sci. 38: 47-55. PMID: 15795123
- Nadifloxacin downmodulates antigen-presenting functions of epidermal Langerhans cells and keratinocytes. | Murata, K., et al. 2006. J Dermatol Sci. 42: 91-9. PMID: 16431082
- Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. | Jacobs, MR. and Appelbaum, PC. 2006. Expert Opin Pharmacother. 7: 1957-66. PMID: 17020421
- [Effect of the admixture of tetracycline and nadifloxacin ointments on their stability and their antibacterial activity]. | Kawamoto, T., et al. 2008. Yakugaku Zasshi. 128: 1221-6. PMID: 18670189
- In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany. | Alba, V., et al. 2009. Int J Antimicrob Agents. 33: 272-5. PMID: 19095414
- Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones. | Oppegard, LM., et al. 2010. Antimicrob Agents Chemother. 54: 3011-4. PMID: 20404126
- Nadifloxacin downregulates the production of matrix metalloproteinases in the human epidermal keratinocyte cell line HaCaT. | Hosoda, S., et al. 2012. J Dermatol. 39: 855-7. PMID: 22220987
- Design and evaluation of microemulsion gel system of nadifloxacin. | Shinde, U., et al. 2012. Indian J Pharm Sci. 74: 237-47. PMID: 23439454
- Efficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies. | Narayanan, V., et al. 2014. Dermatol Ther (Heidelb). 4: 233-48. PMID: 25212256
- Validated high-performance thin-layer chromatographic (HPTLC) method for simultaneous determination of nadifloxacin, mometasone furoate, and miconazole nitrate cream using fractional factorial design. | Patel, KG., et al. 2016. J Food Drug Anal. 24: 610-619. PMID: 28911568
- A Validated Ultra-Performance Liquid Chromatographic Method for the Simultaneous Determination of Nadifloxacin, Mometasone Furoate and Miconazole Nitrate in Their Combined Dosage Form and Spiked Human Plasma Samples. | Tarek, M., et al. 2020. J Chromatogr Sci. 57: 867-873. PMID: 31602483
- Recent Advances Regarding the Therapeutic Potential of Adapalene. | Rusu, A., et al. 2020. Pharmaceuticals (Basel). 13: PMID: 32872149
- Glycosides of Nadifloxacin-Synthesis and Antibacterial Activities against Methicillin-Resistant Staphylococcus aureus. | Hutchins, M., et al. 2022. Molecules. 27: PMID: 35268604
- Co-crystal of nadifloxacin with oxalic acid. | Karthammaiah, GN., et al. 2023. Acta Crystallogr E Crystallogr Commun. 79: 319-322. PMID: 37057007
- Effect of nadifloxacin on neutrophil functions. | Akamatsu, H., et al. 1995. J Int Med Res. 23: 19-26. PMID: 7774755
Inhibitor of:
Topo II.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nadifloxacin, 250 mg | sc-202723 | 250 mg | $108.00 | |||
Nadifloxacin, 1 g | sc-202723A | 1 g | $316.00 |